A noninferiority randomized open-label pilot study of 3- versus 7-day influenza postexposure prophylaxis with...

Area of Science:

• Pediatric Infectious Diseases
• Clinical Pharmacology

Background:

• Short-course influenza postexposure prophylaxis (PEP) has demonstrated efficacy in adults, but data in pediatric populations are limited.
• Influenza remains a significant cause of morbidity in hospitalized children.

Purpose of the Study:

• To evaluate the noninferiority of a 3-day versus a 7-day course of oral oseltamivir for influenza PEP in hospitalized children.
• To compare the efficacy, adverse events, and costs associated with different durations of influenza PEP in pediatric patients.

Main Methods:

• A randomized open-label pilot trial comparing 3-day versus 7-day oseltamivir prophylaxis in pediatric influenza contacts.
• Intention-to-treat (ITT) and per-protocol (PP) analyses were conducted to assess efficacy.
• Relative risk of adverse events (AEs) and cumulative costs were compared between groups.

Main Results:

• Both 3-day and 7-day oseltamivir PEP regimens demonstrated high efficacy (100% and 93.6% in ITT, respectively), with noninferiority confirmed within the predefined margin.
• No significant differences in adverse events were observed between the 3-day and 7-day prophylaxis groups.
• The 3-day PEP regimen was associated with significantly lower cumulative costs for drugs and adverse event management compared to the 7-day regimen.

Conclusions:

• A 3-day course of oseltamivir for influenza postexposure prophylaxis is noninferior to a 7-day course in hospitalized children.
• Shorter duration influenza PEP (3 days) offers a cost-effective alternative to longer regimens.
• This pilot study supports the use of shorter-duration oseltamivir prophylaxis in pediatric settings.